Web Content Display Web Content Display

Gateway to Asia-Pacific
Header Arrow

Web Content Display Web Content Display


Web Content Display Web Content Display

Partnering is a critical component of Menarini Asia-Pacific's business model. As multinational healthcare companies re-prioritize portfolios and seek experienced and trusted partners to enter large and emerging markets, Menarini Asia-Pacific provides the one stop advice and tailor made solutions for partners desiring to enter single or multiple markets across the region.

Check BulletWe pride ourselves in creating productive and profitable alliances. Menarini Asia-Pacific offers its partners a single point of entry into all major Asia-Pacific markets.

Check BulletWorking closely with our partners through dedicated Alliance Management teams, we partner products at various stages in their development lifecycle, commencing from clinical research and local regulatory approval through to launch and on-going commercialization, as well as products undergoing lifecycle management.

Becoming a partner with Menarini Asia-Pacific provides companies with the opportunity to maximize the value of their existing portfolios, by simplifying the process of commercializing their assets in a number of diverse and complex regional markets, while at the same time minimizing the risks involved. In addition, Menarini Asia-Pacific is dedicated to upholding the same high international standards of compliance and transparency expected of all its partners.

Menarini Asia-Pacific leverages its significant regional experience with Asian patient and physician insights, as well as world class resources, to provide an unflinching commitment to its partners.

Our partner solutions include:

Brand Acquisition
Co-promotion / Marketing Opportunities


Our team excels in execution, and has a consistent track record in delivering strong sales and attractive returns. The deep regional experience and depth of our sales and marketing teams offers partners the flexibility of various models of collaboration.

For more information on partnering with Menarini Asia-Pacific, please contact us.

Key Deals

Web Content Display Web Content Display

Web Content Display Web Content Display

Licensing Agreement to Commercialize SPEDRA™ in 10 Asia-Pacific countries

Mitsubishi Tanabe Pharma Corporate (MTPC) and Menarini Asia-Pacific have entered into a licensing agreement to commercialize and promote Menarini SPEDRA™ in 10 countries in Asia-Pacific, including: China, Hong Kong, Macao, Taiwan, Indonesia, Malaysia, Philippines, Singapore, Thailand and Vietnam. SPEDRA™ (avanafil) is a new and innovative phosphodiesterase – 5 inhibitor (PDE5-i) approved by the European Commission in June 2013 for the treatment of erectile dysfunction. For more information, please refer to the Press Release.

Web Content Display Web Content Display

Side Panel Logo Side Panel Logo Side Panel Logo Side Panel Logo Side Panel Logo Side Panel Logo